and CSD sites infrequently have BRAF mutations, but commonly have amplifications or activating mutations of KIT. 8, 9 KIT is a type III transmembrane receptor tyrosine kinase. 10 Binding of its ligand, stem cell factor, results in receptor dimerization, autophosphorylation, and activation of several signaling pathways; thereby, mediating cancer cell growth, proliferation, invasion, metastasis, and inhibition of apoptosis.
The importance of KIT in normal melanocyte development is well established [11] [12] [13] ; however, its role as an oncogene and therapeutic target in melanoma has only recently become clear. Although KIT is expressed in some melanomas, loss of expression is observed with progression of disease from superficial to invasive to metastatic stages, suggesting that KIT possesses tumor suppressive functions.
14-18 Furthermore, 3 phase 2 studies of metastatic melanoma treated with imatinib mesylate, an orally available ATP-competitive inhibitor of several tyrosine kinases including KIT, did not demonstrate clinical activity. [19] [20] [21] These trials accrued before the discovery of activating mutations of KIT in melanoma and did not select patients based on the presence of KIT mutations or amplification.
KIT is an established therapeutic target in cancers with activating mutations of KIT, such as gastrointestinal stromal tumors (GIST), and significant benefit is achieved with various small molecule inhibitors of KIT including imatinib mesylate. 22 Several melanoma cell lines with KIT mutations are highly sensitive to imatinib mesylate. [23] [24] [25] Furthermore, several patients with melanoma harboring KIT alterations, including a K642E mutation as well as a 7-codon duplication of exon 11, have been reported to achieve major durable responses to imatinib mesylate. 26, 27 Given the preclinical and anecdotal clinical activity of imatinib mesylate observed in KIT mutant melanoma, we conducted this study to test the hypothesis that inhibition of KIT in a molecularly selected subgroup of patients with melanomas harboring mutations or amplification of KIT will result in objective regression and disease control. We further explored whether the identification of functionally relevant KIT alterations would allow us to better select patients most likely to respond to KIT inhibition.
METHODS

Patients
Between April 23, 2007 , and April 16, 2010 , 328 patients were enrolled from 1 community and 5 academic oncology centers in the United States for molecular screening and determination of eligibility. Eligible patients included those patients aged 18 years or older with metastatic melanoma arising from acral, mucosal, and body sites with signs of CSD harboring mutations or amplification of KIT. Patients required an Eastern Cooperative Oncology Group performance status of 0 (able to be fully active and perform all predisease activities without restriction), 1 (unable to perform physically strenuous activity but ambulatory and able to perform work of a light or sedentary nature, such as light housework or office work), or 2 (ambulatory and capable of all self-care, but unable to perform any work activities), 28 life expectancy of 3 months or longer, measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST), 29 and adequate bone marrow, hepatic, and renal function. Prior systemic therapy and treated stable brain metastases were permitted.
All patients were informed of the investigational nature of the study and provided written informed consent in accordance with institutional and federal guidelines. The protocol was approved by each center's institutional review board. Race/ethnicity was selfreported by the participants.
Molecular Screening
Tumor specimens were tested for KIT mutations and amplification. DNA for mutation analysis was extracted from formalin-fixed, paraffin-embedded specimens as previously published. 30 Polymerase chain reaction assays using primers specific for KIT exons 9, 11, 13, 17, and 18; NRAS exons 1 and 2; BRAF exon 15; and GNAQ exon 5 were used, followed by Sanger sequencing. Polymerase chain reaction products were purified using ExoSAP-IT (USB Corporation, Cleveland, Ohio) and directly sequenced in the forward and reverse directions using the Applied Biosystems 3730 capillary DNA analyzer (Applied Biosystems, Foster City, California).
Fluorescence in situ hybridization was performed on formalin-fixed, paraffinembedded sections as previously described. 23 Human BAC clones RP11-722F1 and CTD-3180G20 spanning KIT in 4q12 (Invitrogen, Carlsbad, California), reference clones RP11-365H22 (Wellcome Trust Sanger Institute, Hinxton, Cambridge, England) and RP11-799E21 (BACPAC Resources, Oakland, California) for proximal 4q, and RP11-19F13 (Wellcome Trust Sanger Institute) and RP11-461G20 (BACPAC Resources) proximal 4p were used. 31 . Amplification was defined as a KIT-to-centromere ratio of more than 2.5, with a ratio of more than 10 representing highlevel amplification. Polysomy was defined as the presence of discrete red, orange, and green signal groups.
Study Procedures
Patients whose tumors harbored a KIT alteration were eligible to receive imatinib mesylate, 400 mg orally twice daily in 6-week cycles until unacceptable toxicity or disease progression. Imatinib mesylate was supplied by the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Imatinib mesylate was reduced to 400 mg/d in the setting of toxicity, with one further reduction to 300 mg/d permitted. Study participation was discontinued if adverse effects persisted. KIT Radiographic imaging and tumor measurementswereperformedwithin4weeks of treatment initiation, every 6 weeks for 18 weeks, and every 12 weeks subsequently. Response was judged according to RECIST version 1.0. 29 All RECIST responses were confirmed by a central radiologist(J.T.).Tobeconsidereddurable, changes in tumor measurements were confirmedbyrepeatradiologicassessment performed no less than 6 weeks after the initial response was observed. Stable disease was defined as a less than 30% decreaseorlessthan20%increaseinthesum of the longest diameters of the target lesions, taking as reference the baseline tumor measurements. Patients receiving 2 or more weeks of imatinib mesylate were evaluable for response. Patients receiving at least 1 week of imatinib mesylate were evaluable for toxicity.
Statistical Analysis
The primary end point of this singlegroup, open-label, phase 2 study was durable objective response defined as partial response or complete response according to RECIST version 1.0. 29 Secondary end points included time to progression, overall survival, and correlation of molecular alterations and clinical response.
A Simon 2-stage mini-max design 32 was used to assess the primary end point of response, with the following parameters: 10% not promising response rate, 30% promising response rate, and .10 type I and II error rates. If 1 or more durable responses were observed in the first 16 evaluable patients, accrual continued until 25 evaluable patients were identified. If 5 or more durable responses were observed, imatinib mesylate would be considered worthy of further testing in this patient population. Survival time was defined as the time from initiation of imatinib mesylate to the date of death or last follow-up. Time to progression was defined as the time from initiation of imatinib mesylate to the date of progression or last follow-up. Survival distributions were estimated using the Kaplan-Meier method. 33 Comparisons were made by log-rank test. Baseline patient characteristics and adverse events were reported using summary statistics and frequency tables. Adverse events were reported as the most severe manifestation of each event category during any cycle of treatment. Fisher exact test was used to compare molecular alteration and response. Statistical analysis was conducted using SAS version 9.2 (SAS Institute Inc, Cary, North Carolina). All significance tests were 2-sided and used a 5% level of significance.
RESULTS
Molecular Screening
Threehundredtwenty-eightpatientsconsented to molecular screening. The flow of patients and tumor testing is shown in eFigure 1 (available at http://www.jama .com). Mutation status for KIT, BRAF, NRAS, and GNAQ, and KIT amplification status was determined in 295 cases, including 85 acral melanomas, 93 mucosal melanomas, and 87 melanomas clinically determined to arise from CSD sites. CSD indicates melanoma arising from chronically sun-damaged skin; NA, not applicable. The melanoma subtype, KIT mutational and amplification status, the ratio of mutant to wild-type alleles as determined by their respective electropherogram peak heights, and the RECIST (Response Evaluation Criteria in Solid Tumors) response achieved for each patient treated with imatinib mesylate is shown. Amplification was defined as a KITto-centromere ratio of 2.5 or more, with the pattern of amplification described as uniform (homogeneous) or mixed (heterogeneous) across the tumor specimen. The best response as determined by RECIST is identified by the color of the bar. The length of the bar represents the duration of time in weeks that each patient remained receiving therapy. a Mutations previously identified in melanoma 8, 9 and gastrointestinal stroma tumors. 35, 36 b Tumors with mutant to wild-type allelic ratios of more than 1:1, which are those hypothesized most likely to respond to therapy with KIT inhibition. c Patients receiving treatment at the time of this report.
and KIT alteration identified for each evaluable patient are shown in FIGURE 1.
Representative radiographic images of patients achieving responses are shown in FIGURE 2. Because 2 of the 6 responses were transient and not sustained on a follow-up scan performed 6 weeks after the initial response was documented, the predetermined end point of 5 responses of 25 evaluable patients who were treated was not met. The median time to progression was 12 weeks (interquartile range [IQR], 6-18 weeks; 95% CI, 11-18 weeks). The 4 patients who achieved durable responses maintained disease control for more than 1 year. Durable disease control was observed in patients achieving stable disease, with 2 such patients maintaining stability for more than 6 months. Median survival from the time of initiation of therapy was 46.3 weeks (IQR, 28 weeks-not achieved; 95% CI, 28 weeks-not achieved), with 10 patients (40%) alive at the time of analysis (FIGURE 3) .
Five patients underwent optional serial tumor biopsies to determine histopathological and immunohistochemical effects of therapy. One case demonstratingdecreasedcellularityandreduced tumor proliferation in a clinically responding metastasis compared with both pretreatment sample as well as a clinically progressing lesion is shown in eFigure 3.
Association of Molecular Alterations and Clinical Response
We observed that KIT mutations are widely distributed over the coding region as shown in eFigure 2. Many KIT mutations identified in our study have not previously been reported in melanoma 8, 9 or GIST 35, 36 and were present only in individual cases, suggesting that some may represent passenger mutations rather than bona fide driver alterations. Specific amino acid changes encountered repeatedly in cancer are likely to be of functional relevance. Interestingly, all 6 responses occurred in tumors with L576P or K642E mutations, the most common mutations in melanoma. 8, 9 The proportion of responders 
Representative patient with vulvovaginal mucosal melanoma
Representative patient with acral melanoma MRI indicates magnetic resonance imaging; PET, positron emission tomography. MRI and PET scans from a representative patient with vulvovaginal mucosal melanoma harboring both an exon 11 L576P mutation and amplification of KIT are shown at baseline (yellow arrows, A and C) and after 6 weeks of therapy with imatinib mesylate (yellow arrows, B and D). The arrowhead in A indicates a heterogeneous multilobulated mass distending the entire vagina and extending inferiorly to the introitus. This lesion demonstrates intense fluorodeoxyglucose uptake on PET imaging (arrowhead in C). After 6 weeks of therapy with imatinib mesylate, there was significant shrinkage in the size of this mass with interval resolution of hypermetabolic activity (arrowheads in B and D indicate baseline locations of tumor). This patient ultimately achieved a complete radiographic response to therapy at her week 12 scan. Baseline and posttreatment PET images of a second representative patient with an acral melanoma harboring an exon 11 576P mutation and amplification are shown in E and F. This patient ultimately achieved a complete radiographic and pathological response to therapy at his week 12 scan.
observed in the 13 cases whose tumors harbored mutations recurrently found in GIST 37, 38 or melanoma 8, 9 (V559C, L576P, V642E, and N822K) is 46%, higher than in the group as a whole.
Another method to separate driver from passenger mutations is to identify evidence of positive selection for the mutation. We investigated whether relative abundance of mutant KIT influenced response to imatinib mesylate in 2 ways. First, we assessed whether patients with tumors harboring KIT that was both mutated and amplified were more likely to achieve tumor response than those patients whose tumors harbored either alteration alone. Although a greater likelihood of response was observed in these cases, the difference was not statistically significant (36%; 95% CI, 15%-65%; vs 14%; 95% CI, 4%-40%; P=. 35) .
We then evaluated whether the ratio of the mutant to wild-type KIT allele influenced response to imatinib mesylate. Mutations associated with a mutant to wild-type allele ratio of more than 1 are likely to be pathogenetically relevant. In a pure population of diploid tumor cells with a heterozygous mutation, this ratio is expected to be 1. As tumor samples typically contain normal cell contamination, the allelic ratio of heterozygous samples is often smaller than 1. Allelic ratios of more than 1 indicate the presence of an independent genetic event, such as amplification of the mutant allele, deletion of the wild-type allele, or loss of heterozygosity, which shifts the ratio in favor of the mutant allele. Such positive selection of the mutated allele suggests that the mutation is 
Time to progression
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Kaplan-Meier curves for overall survival (15 deaths) and time to progression (22 progression events) of the 25 evaluable patients are shown. The median overall survival was 10.7 months (95% confidence interval [CI], 6.5 months-not achieved) and the median time to progression was 2.8 months (95% CI, 2.5-4.0 months). Mutations repeatedly identified in melanoma or gastrointestinal stromal tumors and those associated with a mutated to wild-type allele ratio of more than 1 are those most likely to be pathogenetically relevant. The subset of patients with tumors harboring such alterations achieved an overall survival and time to progression greater than that achieved in cases without such characteristics. 
COMMENT
These results demonstrate that a subset of melanomas with genetic alterations of KIT respond to treatment with imatinib mesylate. Durable responses were observed in 16% (95% CI, 2%-30%) of these patients, with all sustained for more than 1 year. Two additional responses were observed but not sustained on a follow-up scan performed 6 weeks after the initial response was documented. Therefore, this study did not meet its predetermined end point. Nevertheless, the responses achieved in this population preselected based on the presence of KIT mutations or amplification compare favorably to that observed in prior trials of molecularly unselected patients, [19] [20] [21] in which response was limited to 1 of 62 evaluable participants treated.
This study additionally highlights the challenges in identifying appropriate patients for treatment with KIT inhibition. Seventy-four percent of BRAF mutant melanomas harbor a substitution of glutamic acid for valine at amino acid 600 (the V600E mutation). 39 By contrast, mutations in KIT are more widely distributed over the coding region. Treatment of patients with melanoma harboring the oncogenic V600E BRAF mutation with an effective inhibitor of RAF, such as PLX4032 (Plexxikon, RG7204; Roche Pharmaceuticals, Basel, Switzerland), results in tumor response in 81% of cases. 40 The more modest results in this study suggest that only select KIT alterations are truly oncogenic and indicative of an effective therapeutic target.
By using more selective molecular criteria, we may better identify patients who will respond to imatinib mesylate. Response to imatinib mesylate is predicted to be dependent on the region of the protein affected by a mutation, with some mutations affecting the binding affinity of imatinib mesylate to KIT as previously demonstratedininvitroandclinicalstudies of GIST. 35, 37, 41 Prior observations in GIST demonstrated the sensitivity of K642E and N822K mutations and the resistance of V654A and D820Y mutations to imatinib mesylate. 35, 41, 42 Concordant with these findings, patients with melanomaharboringtheseresistantmutations progressed, although disease stability and responses were observed in those patients whose tumors harbored K642E and N822K mutations (Figure 1 ). Imatinib mesylate-resistance in GIST commonly results from the development of secondary KIT mutations, including V654A, D820Y, N822K, and A829P. 35, 36 These mutations were identified as primary mutationsinseveralmelanomasandmayalso predict a lower probability of response with imatinib mesylate. Indeed, the best response we observed in such cases was stable disease. Importantly, although an in vitro study demonstrated poor sensitivity of a melanoma cell line harboring anL576Pmutationtoimatinibmesylate, 43 we observed dramatic in vivo responses inpatientswithmelanomasharboringthis mutation.
To separate bona fide driver from passenger alterations of KIT, we sought evidence for tumor selection of specific mutations. We observed that imatinib mesylate has greater activity in tumors harboring recurrent KIT mutations found in melanoma or GIST, as well as in tumors with a mutant KIT allele in greater abundance than the wild-type allele. When combining those patients whose tumors have an allelic ratio of more than 1 with those whose tumors harbor recurrent primary mutations found in GIST or melanoma, we observed a better response rate, time to progression, and overall survival compared with other cases (Figure 3 ). These criteria may serve as indicators of genetic events relevant to oncogenesis and should be investigated further as predictive markers of response to KIT inhibition.
In conclusion, our data show that imatinib mesylate therapy in patients with melanoma harboring specific KIT alterations results in clinical responses, consistent with the paradigm of oncogene addiction. 44 Prediction of response to KIT inhibition can be improved beyond what we report herein by identifying tumors that harbor KIT alterations of functional relevance.
